Arialys Therapeutics

La Jolla, CA · Founded 2021 · Privately Held (backing)

Operator of a clinical-stage biotechnology company intended to pioneer new precision medicines for autoimmune neuropsychiatric diseases. Arialys Therapeutics is based in La Jolla, CA and was founded in 2021. It was valued at $112 million at its seed round in Jun 2025, the last priced event on record. It has raised $72 million across 2 recorded rounds; the latest was a $14.8 million early-stage round in Jun 2025.

PMV mark · valuation
$112.0M
Oct 2026
Priced at
its seed round
Jun 2025
Total raised
$72.0M
Last round
Early Stage VC
Jun 2025
What is Arialys Therapeutics worth?
$112.0MPrivateMarketView mark · Oct 2026

Valued at $112.0M at its seed round, Jun 2025. Nothing has traded since.

Free account
More of Arialys Therapeutics with a free account
  • ·Watch Arialys Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Arialys Therapeutics funding history

2 rounds
DateRoundRaisedPost-money
Jun 2025Early Stage VC$14.8M▮
Nov 2022Early Stage VC$14.3M▮
Unlock post-money valuations

Membership and data by Private Market View

Arialys Therapeutics valuation

Arialys Therapeutics was valued at $112 million at its seed round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Arialys Therapeutics raised?

Arialys Therapeutics has raised $72 million in total; 2 of its rounds are on record. The largest on record was a $14.8 million early-stage round in Jun 2025.

Arialys Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently in Jul 2025 ($14.8 million sold to 7 investors).

How Arialys Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Arialys Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Arialys Therapeutics

What is Arialys Therapeutics worth?
Arialys Therapeutics is valued at $112.0M as of Oct 2026. Valued at $112.0M at its seed round, Jun 2025. Nothing has traded since.
How much has Arialys Therapeutics raised?
Arialys Therapeutics has raised $72.0M in total funding across 2 recorded rounds.
When did Arialys Therapeutics last raise?
Arialys Therapeutics last raised in Jun 2025 (Early Stage VC), raising $14.8M.